Four years experience with dura mater cardiac valves.
The clinical use of homologous dura mater cardiac valves was begun in January 1971. Between January 1971 and May 1975, 751 patients received 849 dura mater valves: 428 mitral, 365 aortic, 52 tricuspid and 4 pulmonary. The hospital mortality observed in this series was 13.6% and late mortality was 2.5%. The main causes of death were low-output syndrome in the immediate post-operative period or cardiac failure in the late post-operative period, due to myocardial impairment. Paravalvular leaks and errors in the manufacture of the valve were the main causes of regurgitation both in the immediate and late post-operative period. The incidence of thromboembolism, bacterial and fungal endocarditis was: 0.79%, 0.39%, 0.53% respectively. The results obtained with dura mater valve in a period of four years are satisfactory from the clinical and hemodynamic points of view.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001021:Aortic Valve / Q000601:surgery; D001228:Aspergillosis / Q000209:etiology; D001232:Aspergillus fumigatus; D002648:Child; D002675:Child, Preschool; D004388:Dura Mater / Q000637:transplantation*; D004696:Endocarditis / Q000209:etiology; D006351:Heart Valves / Q000601:surgery*; D006801:Humans; D008722:Methods; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery; D011183:Postoperative Complications; D011664:Pulmonary Valve / Q000601:surgery; D013530:Surgical Wound Infection; D013923:Thromboembolism; D014184:Transplantation, Homologous; D014261:Tricuspid Valve / Q000601:surgery